Summary: A carbamate-derived reversible CHOLINESTERASE INHIBITOR that is selective for the CENTRAL NERVOUS SYSTEM and is used for the treatment of DEMENTIA in ALZHEIMER DISEASE and PARKINSON DISEASE.

Top Publications

  1. Rosler M, Anand R, Cicin Sain A, Gauthier S, Agid Y, Dal Bianco P, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ. 1999;318:633-8 pubmed
    To assess the effects of rivastigmine on the core domains of Alzheimer's disease. Prospective, randomised, multicentre, double blind, placebo controlled, parallel group trial...
  2. Makris M, Koulouris S, Koti I, Aggelides X, Kalogeromitros D. Maculopapular eruption to rivastigmine's transdermal patch application and successful oral desensitization. Allergy. 2010;65:925-6 pubmed publisher
  3. Takeda M, Tanaka T, Okochi M. New drugs for Alzheimer's disease in Japan. Psychiatry Clin Neurosci. 2011;65:399-404 pubmed publisher
  4. Tricco A, Soobiah C, Berliner S, Ho J, Ng C, Ashoor H, et al. Efficacy and safety of cognitive enhancers for patients with mild cognitive impairment: a systematic review and meta-analysis. CMAJ. 2013;185:1393-401 pubmed publisher
    ..Our eligibility criteria were studies of the effects of donepezil, rivastigmine, galantamine or memantine on mild cognitive impairment reporting cognition, function, behaviour, global status, ..
  5. Golüke N, van Strien A, Dautzenberg P, Jessurun N, Keijsers C. Skin lesions after oral acetylcholinesterase inhibitor therapy: a case report. J Am Geriatr Soc. 2014;62:2012-3 pubmed publisher
  6. Tabani H, Asadi S, Nojavan S, Parsa M. Introduction of agarose gel as a green membrane in electromembrane extraction: An efficient procedure for the extraction of basic drugs with a wide range of polarities. J Chromatogr A. 2017;1497:47-55 pubmed publisher
    ..extraction (EME) without using any organic solvent, for the extraction of four model basic drugs (rivastigmine (RIV), verapamil (VER), amlodipine (AML), and morphine (MOR)) with a wide polarity window (log P from 0.43 to 3...
  7. Kandiah N, Pai M, Senanarong V, Looi I, Ampil E, Park K, et al. Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson's disease dementia. Clin Interv Aging. 2017;12:697-707 pubmed publisher
    Several studies have demonstrated clinical benefits of sustained cholinesterase inhibition with rivastigmine in Alzheimer's disease (AD) and Parkinson's disease dementia (PDD)...
  8. Park K, Kim E, Han H, Shim Y, Kwon J, Ku B, et al. Efficacy and tolerability of rivastigmine patch therapy in patients with mild-to-moderate Alzheimer's dementia associated with minimal and moderate ischemic white matter hyperintensities: A multicenter prospective open-label clinical trial. PLoS ONE. 2017;12:e0182123 pubmed publisher
    ..We aimed to compare the effects of the rivastigmine patch between patients with AD with minimal WMHs and those with moderate WMHs...
  9. Suzuki Y, Kamijo Y, Yoshizawa T, Fujita Y, Usui K, Kishino T. Acute cholinergic syndrome in a patient with mild Alzheimer's type dementia who had applied a large number of rivastigmine transdermal patches on her body. Clin Toxicol (Phila). 2017;55:1008-1010 pubmed publisher
    ..Three hours later, 10 transdermal patches, each containing 18?mg of rivastigmine (9...

More Information


  1. Mohammad D, Chan P, Bradley J, Lanctot K, Herrmann N. Acetylcholinesterase inhibitors for treating dementia symptoms - a safety evaluation. Expert Opin Drug Saf. 2017;16:1009-1019 pubmed publisher
    ..Areas covered: Donepezil, galantamine and rivastigmine are the three AChEIs approved for the treatment of varying stages of AD...
  2. Muñoz Moreno J, Prats A, Molto J, Garolera M, Perez Alvarez N, Diez Quevedo C, et al. Transdermal rivastigmine for HIV-associated cognitive impairment: A randomized pilot study. PLoS ONE. 2017;12:e0182547 pubmed publisher
    To assess the efficacy and safety of transdermal rivastigmine for the treatment of HIV-associated cognitive impairment...
  3. Panek D, Wichur T, Godyń J, Pasieka A, Malawska B. Advances toward multifunctional cholinesterase and β-amyloid aggregation inhibitors. Future Med Chem. 2017;9:1835-1854 pubmed publisher